SciLifeLab Drug Discovery & Development

New Modalities Nordic Investor Forum: Key Takeaway series (1/3) 🔥 “Be proud of what you have here and become better to showcase it globally” 🌍 We kicked off the New Modalities Nordic Investor Forum, hosted by New Modality Support and SciLifeLab Drug Discovery & Development, with an insightful panel discussion on how academia, industry, and government unite to accelerate next-generation therapeutics: 🔹 Bridging the Valley of Death Startups in advanced therapeutics face steep hurdles between early-stage research and market readiness. The panel emphasized the need for task forces, public funding, and infrastructure to support this critical phase, especially when academic founders aren’t equipped to commercialize alone. 🔹 Think Global, Act Local While Sweden and the Nordics have strong ecosystems, the panel urged a shift from national to international mindsets. Europe-wide and global partnerships are key to scaling innovation, accessing funding, and conducting clinical trials. Sweden needs to be better at pan-European syndication and securing EU resources. This might be facilitated in the future via smaller and adaptable grants, an important tool needed for the development of new therapeutic modalities. 🔹 Data is Currency Investors and industry need robust data to make decisions. Yet startups in the Nordics often lack the capital to generate it. Bridging this gap with smarter funding models and in-kind data partnerships can de-risk projects and provide the evidence base investors and industry crave. 🔹De-risking early and in-kind “Define your problem, seek help early and be transparent” is a useful universal recipe for early startup de-risking and should be kept in mind. The ecosystem if filled with experienced actors ready to contribute expertise. In the Nordics many are willing to help you in kind and that is a valuable input most effective if engaged early. Be you a startup, an investor or public entity, it is important to demystify new therapeutic modalities and seek help when navigating regulatory, technical and commercial hurdles. 🔹 Education & Ecosystems Matter The lessons learned Today need to reach the next generation of scientists, investors and health professionals. Building environments that foster daily interaction between disciplines, education and innovation hubs were seen as foundational to long-term success. In addition, not every hub should be doing the same, instead specialize first in what you do best and let the fruits of each hub/regions interact together to foster uniqueness. 👏 A big thank to our panellists Fredrik Wessberg (CCRM Nordic), Stefan Jovinge (Skånes universitetssjukhus (Skåne University Hospital), Magnus Björsne (BioVentureHub), Jenny Nyström (University of Gothenburg), and Anna Bergstrand from Vinnova for steering the discussions. ⭐ What resonated most with you? 💭 Drop your thoughts, questions, or tag a colleague who should weigh in! 📫 Stay tuned for our next key takeway!

🚀 SciLifeLab Science Summit 2025: Drugging the Undruggable Have you registered yet? On October 1st in Aula Medica, Stockholm, we’ll bring together world-leading researchers, industry experts, and innovators to explore disruptive technologies for drugging the undruggable. Why join? ✅ Gain knowledge on the latest breakthroughs shaping drug discovery, precision medicine, and new treatments ✅ Engage with top researchers and industry leaders driving change in the field ✅ Get the opportunity to position your own research for innovation Speakers: * Ray Deshaies, Ph.D. Amgen / Caltech * Annemieke Aartsma-Rus, Leiden University Medical Center * Eva Nittinger, AstraZeneca * Dario Neri, Philogen S.p.A. / ETH Zürich * Filipe Pereira, Lund University * Anders Gabrielsen, Ribocure Pharmaceuticals AB * Jessica Martinsson, SwedenBIO * Mia Phillipson, SciLifeLab 🔗 Don’t miss it — register today: https://lnkd.in/d3RT2stZ